Join us for talks, case studies and advice to inspire academics and researchers in their journey to create commercial impact from research through the formation of spin-out companies.
Highlights of the event include:
Headline speaker: Nobel Laureate Sir Greg Winter
Sir Greg Winter is a Nobel Prize-winning English molecular biologist best known for his work on the therapeutic use of monoclonal antibodies, credited with having invented techniques to both humanise (1986) and, later, to fully humanise using phage display, antibodies for therapeutic uses. Sir Greg has established hugely successful spin out companies including Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics.
Founder stories from award winning spin-out companies, including:
Agenda
15.00 | Arrival and refreshments |
15.30 | Introduction – Anne Ferguson-Smith, Pro-Vice-Chancellor for Research and the Arthur Balfour Professor of Genetics at the University of Cambridge |
15.40 | Fireside chat with Sir Greg Winter |
16.10 | What makes a good spin-out Diarmuid O’Brien, CEO of Cambridge Enterprise Andrew Williamson, Managing Partner of Cambridge Innovation Capital |
16.20 | Founder stories Hannah Sore, CEO, Co-founder & Board of Directors of PharmEnable Florin Udrea, Founder and Chief Technology Officer (CTO) of Cambridge GaN Devices Fiona Karet, Professor of Nephrology, University of Cambridge and Founding Director, Kalium Health Ltd |
17.00 | Q&A panel |
17.30 – 18.30 | Networking drinks |